TY  - BOOK
AU  - Dimagiba, Sarah R., MD.
AU  - Rivadillo, Pablo L., MD.
TI  - Prevalence of toxic optic neuropathy among patients on ethambutol treatment in a tertiary hospital / 
AV  - OPH 2010 0003 
PY  - 2010///
CY  - Fairview, Quezon City
PB  - Department of Ophthalomogy, FEU-NRMF
KW  - ethambutol toxic optic neuropathy
KW  - ophthalmic parameters
KW  - tuberculosis
N1  - Includes appendices and bibliographical references; RESDOP
N2  - Abstract:  To determine the prevalence of Toxic Optic Neuropathy among patients on ethambutol treatment in a tertiary hospital.  Patients diagnosed with pulmonary tuberculosis at FEU-NRMF Medical Center from January 2009 - April 2010 was referred to Ophthalmology service for baseline distance visual acuity testing, color vision testing and fundus examination prior to the intake of anti-tuberculosis drug which includes ethambutol. Patients were advised to follow up at 2 months, 4 months and 6 months during their treatment, dosage of the drug, co-morbidities such as Diabetes Mellitus and Hypertension as well as ophthalmic parameters were entered into standardized data-collection form, statistically analyzed, and compared.  This study included 113 patients diagnosed with pulmonary tuberculosis, eight of which manifested signs of ethambutol toxicity. Results showed that there was a significant association between duration of treatment, dosage of ethambutol and comorbidities specifically Diabetes and Hypertension with ethambutol toxicity, and the most common ophthalmic parameter affected is color vision, which gradually decreased.  Ethambutol-associated optic neuropathy is an established "ocular" drug complication. Giving the therapeutic dose does not guarantee that the patients will not develop ocular toxicity. Duration of the manifestations greatly vary with the health and the condition of the patient. Associated co-morbidities and old age can hasten the toxic effects of the drug which can eventually lead to detrimental ocular complications.
ER  -